

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

28967/37564B Docket No:

PATENT APPLICATION TRANSMITTAL UNDER 37 C.F.R. 1.53

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Title:

Transmitted herewith for filing is the patent application of

Inventor: Kari Alitalo, Marika Karkkainen, Paula Haiko, Kirsi Sainio, and Kirmo Wartiovaara

VEGF-C OR VEGF-D MATERIALS AND METHODS FOR TREATMENT OF

NEUROPATHOLOGIES

1. Type of Application

	This is a new application for a				
	\boxtimes	utility patent.			
		design patent.			
\boxtimes	This is 30, 20	a continuation-in-part application of prior application no. 10/262,538, filed September 02			
Applica	ation Pa	pers Enclosed			

2.

- Title Page
- 109 Pages of Specification (excluding Claims, Abstract, Sequence Listing & Drawings)
- Page(s) of Claims
- Page(s) of Abstract
- Sheet(s) of Drawings (Figs.1)

 \boxtimes Formal

Informal

111 Sequence Listing

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Patent Application Transmittal and the documents referred to as enclosed therewith are being deposited with the United States Postal Service on September 23, 2003, in an envelope addressed to the Box Patent Application, Commissioner for Patents, P.O. Box 1450, Atexandria, NA 22313-1450 utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No.EV 323778967 US.

Richard Zimmermann

3.	Decla	aration o	r Oath			
			Enclose	d		
				Execut	ed by (cl	neck all applicable boxes)
					Invente	or(s)
						representative of inventor(s) FR 1.42 or 1.43)
						nventor or person showing a proprietary interest on behalf of or who refused to sign or cannot be reached
						The petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 are enclosed. See Item 5D below for fee.
		\boxtimes				signed attorney or agent is authorized to file this application t(s). An executed declaration will follow.
4.	Small	Entity St	tatus			
	\boxtimes	Applic	ant claims	small e	ntity stat	us. See 37 CFR 1.27.
			A small	entity s	tatement	is(are) attached.
5.	Additi	ional Pap	ers Enclo	sed		
			Prelimi	nary Am	endment	
			Informa	tion Dis	closure S	Statement
			Declara	tion of E	Biologica	l Deposit
		\boxtimes	=			y of sequence listing containing nucleotide and/or amino acide listing statement under 37 C.F.R. §1.821 with diskette
			Microfi	che com	puter pro	ogram
			Associa	te Powe	r of Atto	rney
			Verified	l transla	tion of a	non-English patent application
			An assi	gnment	of the inv	vention
			Request	and Ce	rtificatio	n Under 35 U.S.C. 122(b)(2)(B)(i)
		\boxtimes	Return	receipt p	ostcard	
			Other			

6. Pri	iority App	lications l	Under :	35 L	JSC	119
--------	------------	--------------------	---------	------	-----	-----

Certified copies of applications from which priority under 35 USC 119 is claimed are listed below and

are attached.
will follow.

COUNTRY	APPLICATION NO.	FILED
US	60/326,326	October 1, 2001

7. Filing Fee Calculation (37 CFR 1.16)

Utility Application \boxtimes

CLAIMS AS FILED - INCLUDING PRELIMINARY AMENDMENT(S) (IF ANY)							
			SMALL ENTITY		OTHER THAN A SMALL ENTITY		
	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE	
BASIC FEE				\$375.00		\$750.00	
TOTAL	36 x 20	= x	X 9=	\$	X 18 =	\$0.00	
INDEP.	x- 3	= x	X 42 =	\$	X 84 =	\$0.00	
First Presentation of Multiple Dependent Claim			+ 140 =	\$140.00	+ 280 =	\$	
Filing Fee:			e:	\$	OR	\$	

B.		Design Application (\$165.00/\$330.00) Filing	; Fee:	\$
С		Plant Application (\$255.00/\$510.00) Filing	; Fee:	\$
D.	Other	Fees		
		Recording Assignment [Fee — \$40.00 per assignment]		\$
		Petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refused to sign or cannot be reached [Fee — \$130.00]		\$
		Other		\$

8. Method of Payment of Fees

Enclo	Enclosed check in the amount of:							
	Charge Deposit Account No. 13-2855 in the amount of: A copy of this Transmittal is enclosed.	\$						
\boxtimes	Not enclosed							

9. Deposit Account and Refund Authorization

The Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees except the filing fee, which may be required during the pendency of this application under 37 CFR 1.16 or 37 CFR 1.17 or under other applicable rules (except payment of issue fees), to Deposit Account No. 13-2855. A copy of this Transmittal is enclosed.

Please refund any overpayment to Marshall, Gerstein & Borun LLP at the address below.

10. Correspondence Address

Customer No.: 04743

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN 6300 Sears Tower 233 South Wacker Drive Chicago, Illinois 60606-6357 (312) 474-6300 (312) 474-0448 (Telefacsimile)

Niville

\$

By:

Katherine L. Neville Reg. No: 53,379

September 23, 2003